SCHEMBL5753768

SCHEMBL5753768

COc1ccc2cc(C(O)c3cncs3)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
AKR1C3 P42330 6/20 0.44
AKR1C2 P52895 6/20 0.44
PTGS2 P35354 3/20 0.44
PTGS1 P23219 3/20 0.44
TSHR P16473 2/20 0.44
CDC42 P60953 1/20 0.44
RAC1 P63000 1/20 0.44
CYP1A2 P05177 1/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
CYP3A4 P08684 1/20 0.43
PDE10A Q9Y233 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
AKR1C1 Q04828 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7819404 0.76 PTGS1 (0.41) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL5750801 0.75 ABCB11 (0.51) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL5752462 0.73 CYP11B2 (0.55) ABCB11CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL3284398 0.71 AKR1C3 (0.57) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL14741993 0.71 CYP3A4 (0.47) ABCB11CYP1A2CYP3A4CYP2C9SLC6A3
SCHEMBL23255697 0.70 ABCB11 (0.66) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL30355290 0.70 ABCB11 (0.66) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL2423910 0.70 ABCB11 (0.66) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL9120097 0.70 ABCB11 (0.66) ABCB11CYP11B1CYP11B2AKR1C3AKR1C2
SCHEMBL28512510 0.70 ABCB11 (0.53) ABCB11AKR1C3AKR1C2PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084149-B2 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-01 US disclosed
EP-1073640-B1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL (JP) 2005-04-13 EP disclosed
US-20030236274-A1 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-25 US disclosed
US-6573289-B1 Naphthalene derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-03 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236274-A1 Naphthalene derivatives, their production and use CYP17A1, CYP21A2, HSD17B1 ABCB11 738/4885CYP11B1 12/4885CYP11B2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.